Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 73, Issue 2, Pages 232-239Publisher
WILEY
DOI: 10.1111/j.1365-2125.2011.04082.x
Keywords
adverse effects; obesity; pancreatic polypeptide; pharmacokinetics; phase I trial; tolerability
Categories
Funding
- MRC
- BBSRC
- NIHR
- Integrative Mammalian Biology (IMB) Capacity Building Award
- NIHR Imperial Biomedical Research Centre [FP7-HEALTH-2009-241592]
- Wellcome Trust Seeding Drug Discovery Initiative [081627]
- MRC DPFS
- EuroCHIP
- BBSRC DRINC
- Wellcome Trust
- Medical Research Council [G84/6667] Funding Source: researchfish
- National Institute for Health Research [ACF-2006-21-009, CL-2010-21-007] Funding Source: researchfish
- MRC [G84/6667] Funding Source: UKRI
Ask authors/readers for more resources
AIMS The objectives of this phase 1 study were to confirm the tolerability of single ascending subcutaneous doses of PP 1420 in healthy subjects, to assess its adverse effects and to investigate the drug's pharmacokinetics and dose proportionality. METHODS This was a double-blind, placebo-controlled, randomized study. There were three dosing periods. Each subject (n = 12) was randomized to receive one dose of placebo and two ascending doses of PP 1420, given as a subcutaneous injection. Blood samples were taken over 24 h to assess pharmacokinetics. Standard safety and laboratory data were collected. The primary endpoint was the tolerability of PP 1420. The secondary endpoint was exposure to PP 1420 as assessed by C-max and AUC(0, infinity). RESULTS PP 1420 was well tolerated by all subjects with no serious adverse effects. Following single subcutaneous doses of PP 1420 at 2, 4 and 8 mg to male subjects, C-max was reached at a median tmax of approximately 1 h post dose (range 0.32-2.00 h). Thereafter, plasma concentrations of PP 1420 declined with geometric mean apparent terminal elimination t(1/2) ranging from 2.42-2.61 h (range 1.64-3.95 h) across all dose levels. CONCLUSIONS Subcutaneous PP 1420 was well tolerated in healthy human subjects at single doses between 2-8 mg, with no tolerability issues arising. Where observed, adverse events were not serious, and there was no evidence of a dose-relationship to frequency of adverse events. The results therefore support the conduct of clinical trials to investigate efficacy, tolerability and pharmacokinetics during repeated dosing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available